000			02222 a2200529 4500
005			20250515111327.0
264		0	_c20080624
008			200806s 0 0 eng d
022			_a1569-8041
024	7		_a10.1093/annonc/mdm591 _2doi
040			_aNLM _beng _cNLM
100	1		_aBurtness, B A
245	0	0	_aA randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: an Eastern Cooperative Oncology Group study. _h[electronic resource]
260			_bAnnals of oncology : official journal of the European Society for Medical Oncology _cMay 2008
300			_a977-83 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAntibiotics, Antineoplastic _xadministration & dosage
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use
650	0	4	_aCarcinoma, Squamous Cell _xdrug therapy
650	0	4	_aCombined Modality Therapy
650	0	4	_aDisease-Free Survival
650	0	4	_aDocetaxel
650	0	4	_aDrug Administration Schedule
650	0	4	_aDrug Resistance, Neoplasm
650	0	4	_aEpothilones _xadministration & dosage
650	0	4	_aFemale
650	0	4	_aHead and Neck Neoplasms _xdrug therapy
650	0	4	_aHematologic Diseases _xchemically induced
650	0	4	_aHumans
650	0	4	_aInfusions, Intravenous
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aPaclitaxel _xadministration & dosage
650	0	4	_aPeripheral Nervous System Diseases _xchemically induced
650	0	4	_aRecurrence
650	0	4	_aSalvage Therapy
650	0	4	_aSurvival Analysis
650	0	4	_aTaxoids _xadministration & dosage
700	1		_aManola, J
700	1		_aAxelrod, R
700	1		_aArgiris, A
700	1		_aForastiere, A A
773	0		_tAnnals of oncology : official journal of the European Society for Medical Oncology _gvol. 19 _gno. 5 _gp. 977-83
856	4	0	_uhttps://doi.org/10.1093/annonc/mdm591 _zAvailable from publisher's website
999			_c17800286 _d17800286